Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 418 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neonatal Respiratory Distress Syndrome Clear all
Terminated Not applicable Interventional

Stress Index to Individualize Mechanical Ventilation in ARDS

NCT02871102
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Recruitment Maneuver with PEEP and Tidal Volume Optimization
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 21, 2026, 2:41 PM EDT
Not yet recruiting Phase 2 Interventional

Pressure Targeting During High Flow Therapy in Premature Infants

NCT07418502
View directory record Official record
Conditions
Preterm Infants, Respiratory Distress Syndrome (Neonatal), BPD - Bronchopulmonary Dysplasia
Interventions
Pressure Targeted High Flow, CPAP
Procedure
Lead sponsor
University of Texas at Austin
Other
Eligibility
7 Days to 40 Weeks
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
San Diego, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Not applicable Interventional Results available

Extending CPAP Therapy in Stable Preterm Infants to Increase Lung Growth and Function

NCT04295564
View directory record Official record
Conditions
Neonatal, Premature Birth, Respiratory Distress Syndrome
Interventions
Additional 2 weeks of CPAP
Other
Lead sponsor
Cynthia McEvoy
Other
Eligibility
1 Day to 12 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 21, 2026, 2:41 PM EDT
Recruiting No phase listed Observational

Predictive Value of Lung Ultrasound for Respiratory Decompensation in Late Preterm Neonates

NCT07216053
View directory record Official record
Conditions
Pre-Term, Respiratory Distress of Newborn, Premature
Interventions
Point of care lung ultrasound
Diagnostic Test
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
34 Weeks to 36 Weeks
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 2:41 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

NCT05938036
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
ALT-100 mAb, ALT-100 (Placebo)
Drug
Lead sponsor
Aqualung Therapeutics Corp.
Industry
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 21, 2026, 2:41 PM EDT
Withdrawn Phase 1 Interventional

Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study

NCT00431379
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Tenecteplase
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Macon, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients

NCT03058666
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Aerosolized Calfactant, Solarys
Drug · Device
Lead sponsor
ONY
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Mobile, Alabama • Phoenix, Arizona • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 21, 2026, 2:41 PM EDT
Recruiting Phase 2 Interventional

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

NCT06701669
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions
Cohort B: paridiprubart, Cohort B: placebo
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Results available

Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome

NCT01775774
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
San Francisco, California • Stanford, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Not applicable Interventional Results available

Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS

NCT04325906
View directory record Official record
Conditions
Prone Positioning, High Flow Nasal Cannula, Acute Respiratory Distress Syndrome, Corona Virus Infection
Interventions
high flow nasal cannula (HFNC), Prone positioning (PP)
Device · Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Seattle-PAP Bubble Nasal CPAP and Work of Breathing

NCT02210026
View directory record Official record
Conditions
Respiratory Distress Syndrome In Premature Infants, Bronchopulmonary Dysplasia, Newborn Primary Sleep Apnea
Interventions
Seattle-PAP
Device
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Hours to 72 Hours
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 21, 2026, 2:41 PM EDT
Recruiting Phase 3 Interventional

Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

NCT06776783
View directory record Official record
Conditions
Respiratory Distress Syndrome, Pre-term Infants
Interventions
APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system), Control
Combination Product · Other
Lead sponsor
Aerogen Pharma Limited
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
18
States / cities
Little Rock, Arkansas • La Jolla, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide

NCT00569530
View directory record Official record
Conditions
Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction), Bronchopulmonary Dysplasia
Interventions
Infasurf (ONY Inc.), Sham
Drug
Lead sponsor
Roberta Ballard
Other
Eligibility
7 Days to 14 Days
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Berkeley, California • Oakland, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 21, 2026, 2:41 PM EDT
Recruiting Phase 2 Interventional

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

NCT05947955
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Infections
Interventions
Rhu-pGSN, normal saline
Drug
Lead sponsor
BioAegis Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 2:41 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS

NCT07449572
View directory record Official record
Conditions
ARDS (Acute Respiratory Distress Syndrome)
Interventions
HT31-1, Saline (0.9%, sterile, for infusion)
Drug · Other
Lead sponsor
HTIC, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 2:41 PM EDT
Enrolling by invitation No phase listed Observational

The Medical Management in Patients Exposed to Weapons of Mass Destruction

NCT05026645
View directory record Official record
Conditions
Chemical Injury, Chemicals; Intoxication, Acute Respiratory Distress Syndrome, Distress Respiratory Syndrome, Medical Emergencies
Interventions
Clinical interventions performed in acute settings (contaminated environment), Protection (clinician and patient), Decontamination (clinician and patient)
Procedure
Lead sponsor
St. Justine's Hospital
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2036
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Iloprost Effects on Gas Exchange and Pulmonary Mechanics

NCT01274481
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Acute Lung Injury, Pulmonary Hypertension
Interventions
Iloprost
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 21, 2026, 2:41 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Comparison Study of High Frequency Percussive Ventilation With Conventional Ventilation

NCT00308022
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Pneumonia, Mechanical Ventilation
Interventions
High Frequency Percussive Ventilation
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 1Phase 2 Interventional

Zofin (Organicell Flow) for Patients With COVID-19

NCT04384445
View directory record Official record
Conditions
Corona Virus Infection, COVID-19, SARS, Acute Respiratory Distress Syndrome
Interventions
Zofin, Placebo
Biological · Other
Lead sponsor
ZEO ScientifiX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 21, 2026, 2:41 PM EDT
Recruiting Not applicable Interventional

Comparing Surfactant Administration Through Supraglottic Airway and Thin Catheter for Preterm Infants

NCT07030270
View directory record Official record
Conditions
Surfactant, Respiratory Distress Syndrome (Neonatal)
Interventions
Surfactant Administration through Laryngeal or Supraglottic Airway, Surfactant Administration through Thin Catheter
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Hours to 72 Hours
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 2:41 PM EDT
Withdrawn No phase listed Observational

Genetic Variability and Biomarkers in Children With Acute Lung Injury

NCT01048996
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Acute Lung Injury
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Weeks to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 21, 2026, 2:41 PM EDT
Terminated Phase 2Phase 3 Interventional

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

NCT04360096
View directory record Official record
Conditions
SARS-CoV 2, COVID, ARDS, ALI, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Dyspnea
Interventions
ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo
Drug · Device
Lead sponsor
APR Applied Pharma Research s.a.
Other
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
13
States / cities
Fullerton, California • Irvine, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 21, 2026, 2:41 PM EDT
Terminated Phase 4 Interventional Results available

Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome

NCT02164734
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Endotracheal intubation, Laryngeal mask airway, remifentanil
Device · Drug
Lead sponsor
Albany Medical College
Other
Eligibility
2 Hours to 48 Hours
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 3 Interventional

Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)

NCT00000579
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Lung Diseases
Interventions
Low Tidal Volume Ventilation, Positive End-Expiratory Pressure, Lysofylline, Methylprednisolone, Ketoconazole, Fluid Management, Pulmonary Artery Catheter
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2004
U.S. locations
20
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 21, 2026, 2:41 PM EDT